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Suppressor of cytokine signaling 3 (SOCS3) is a potent regulator of cytokine signaling
in macrophages and T cells. In recent studies, evidence has been provided for SOCS3
activation in all major bone cells including osteoclasts, chondrocytes, synoviocytes, and
osteoblasts. The investigation of SOCS3 function in bone remodeling systems implicates
SOCS3 as a key signaling molecule in bone cell-mediated inflammatory responses. Both
pro- and anti-inflammatory functions of SOCS3 have been demonstrated in different types
of bone cells.This review provides an overview of the important role of SOCS3 in inflamma-
tory responses of various bone cells and in bone inflammatory disorders such as periodontal
disease and arthritis. Understanding the roles of SOCS3 in inflammatory diseases of
bone and joints such as arthritis, osteomyelitis, and periodontal diseases is critical to
revealing insights into signaling pathways that can be manipulated in potential therapeutic
approaches.
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INTRODUCTION
Suppressor of Cytokine Signaling 3 (SOCS3) functions as a neg-
ative regulator of cytokine signaling by inhibiting the Janus
Kinase (JAK)-signal transducer and activator of transcription
(STAT) pathways. Expressed ubiquitously in a number of cell
types, including macrophages, neutrophils, and T cells, endoge-
nous SOCS3 may have profound actions in the regulation of
immunity and inflammation (1, 2). In addition, recent studies
have shown SOCS3 to be a significant player in bone-associated
inflammatory responses (3–5). However, the underlying mech-
anisms and signaling pathways regulating SOCS3 expression in
osteoblasts, osteoclasts, and other types of bone cells are still not
well understood.
There are currently eight known SOCS proteins (SOCS1–7
and CIS) that consist of a variable N-terminal region, a central
Src homology-2 (SH2) domain, and C-terminal SOCS box (6).
The SH2 domain is responsible for recognizing phosphotyrosine
motifs of substrates such as JAK or activated cytokine receptors (7).
SOCS proteins bind to activated cytokine receptors or their asso-
ciated JAKs through the SH2 domains, thereby regulating signal
transduction (7). The SOCS box domain constitutes an approxi-
mately 40-amino acid motif that binds elongins B and C as well
as Cullin 5 and RING finger protein Rbx2 to catalyze the ubiq-
uitination of bound signaling proteins (7, 8). The C-terminal
box is thought to regulate SOCS3 protein stability by interact-
ing with elongin C (9). SOCS1 and SOCS3, the two most potent
suppressors of cytokine signaling contain the kinase inhibitory
region (KIR) upstream of their SH2 domain that allows for direct
inhibition of JAK catalytic activity, which in turn suppresses sig-
naling (8, 10, 11). SOCS3 was initially reported to inhibit cytokine
signaling by binding to the activation loop of JAKs; however, it
has been shown that SOCS3 also functions by binding directly
to specific phosphotyrosine motifs of activated cytokine receptor
subunits (9).
SOCS3 IN OSTEOBLASTS
Little data is available for the expression and function of SOCS3
in osteoblasts. Recently, several studies have established the up-
regulation and suppression of SOCS3 in osteoblast-like cell lines
and primary osteoblasts by multiple stimulators (3–5). Addi-
tionally, a negative regulatory role of SOCS3 following pro-
inflammatory stimuli has been demonstrated in osteoblasts (3–5,
10). It was shown that growth hormone (GH) induces the expres-
sion of SOCS3 in UMR 106 cells, a rat osteosarcoma line that
exhibits osteoblast-like properties and expresses a GH-response
JAK2/STAT5 signaling system (3). Furthermore, pre-treatment of
UMR 106 cells with 1, 25-(OH2D3) delayed and decreased the
GH-induced SOCS3 protein expression (3). This in turn suggests
the possibility that 1,25-(OH2D3)-mediated down-regulation of
SOCS3 regulates GH signaling in UMR 106 cells.
To determine the function of SOCS3 in vitro, an osteoblast-
like cell line, MC3T3-E1, and primary osteoblasts were stimulated
with lipopolysaccharide (LPS) from Escherichia coli (E. coli). Cel-
lular RNA was collected to evaluate gene expression of interleukin
(IL)-6 and matrix metalloproteinase (MMP)-13, two notable pro-
inflammatory molecules associated with bone diseases. It was
shown that LPS induces both IL-6 and MMP-13 gene expression
in osteoblasts (4, 5). Additionally, LPS transiently induced SOCS3
in osteoblast-like cells, thereby contributing to the early stage inhi-
bition of LPS-induced IL-6 expression (4). However, endogenous
levels of SOCS3 decreased continuously following LPS stimulation
after 6 h. Moreover, overexpression of SOCS3 drastically inhibited
production of LPS-induced IL-6 by inhibiting transcription fac-
tor, CCAAT/enhancer-binding protein (C/EBP)β, DNA binding
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activity (4). This finding suggests SOCS3 is an important endoge-
nous inhibitory regulator of signal transduction in osteoblasts
following LPS stimulation. However, the study did not report
a direct interaction between SOCS3 and C/EBPβ. Nevertheless,
the data supports that C/EBPβ is critical for LPS-induced IL-6
expression in osteoblasts (4).
SOCS3 exhibited similar inhibitory actions on MMP-13 gene
expression in osteoblast-like MC3T3-E1 cells and primary murine
calvarial osteoblasts (5). We have recently demonstrated that
through overexpression and knockdown of SOCS3 protein,
SOCS3 suppresses MMP-13 transcriptional activity following LPS
stimulation by regulating the p38 MAP Kinase signaling pathway
(5). This observation is consistent with a previous study’s results
that showed that LPS-stimulated MMP-13 transcriptional acti-
vation was significantly reduced by inhibition of p38 MAPK in
murine periodontal ligament (PDL) fibroblasts (12).
Taken together, these findings establish an elementary under-
standing of the expression and function of SOCS3 in osteoblasts.
It is possible that SOCS3 down-regulates additional pro-
inflammatory mediators induced by LPS in osteoblasts, thereby
playing a critical role in osteoblast-mediated immune signal-
ing. In addition, molecular details of SOCS3 regulation of signal
transduction pathways downstream to Toll-like-receptor (TLR) 4
binding remain to be determined.
SOCS3 IN OSTEOCLASTS
The osteoclast is a bone-resorbing cell that, in conjunction with
the osteoblast, contributes to the maintenance of healthy bone
metabolism. Excess osteoclast activity leads to the excessive bone
loss seen in common bone diseases such as osteoporosis, peri-
odontitis, and other clinical conditions (13). While several studies
have established the expression of SOCS3 in osteoclasts, the func-
tional activity of the protein remains controversial, as studies have
reported SOCS3 to be both an inducer and inhibitory regulator of
cytokine signaling (13–15).
The expression of SOCS3 in osteoclasts is induced by a num-
ber of factors, the most studied being transforming-growth factor
β (TGF-β) and receptor of activator of NF-κB ligand (RANKL)
(13, 14). Specifically, SOCS3 gene expression is primarily induced
by the STAT family of transcription factors; however, studies
have suggested that SOCS gene expression can also be achieved
via JAK/STAT-independent activation. For example, in osteoclast
progenitors, RANKL signaling was mediated by the activation of
NF-κB and AP-1 following LPS and IL-1β stimulation; the pro-
moter region of the SOCS3 gene also contains NF-κB and AP-1
binding sites as well as STAT-response elements, suggesting that
its expression can be induced at transcriptional level by these
stimuli (14). Furthermore, sRANKL treatment increased mRNA
levels of both SOCS1 and SOCS3 in bone marrow-derived mono-
cytes/macrophages (M/MO) cells as osteoclast progenitors in a
time-dependent manner (14). In fact, an increase in SOCS levels
was observed as early as 1 h after the addition of sRANKL, peaking
at 5 h, and continuing until 22 h, although levels decreased after 8 h
(14). In addition, sRANKL treatment caused direct induction, and
did not increase levels of SOCS with the addition of cycloheximide
(14). Interestingly, a recent study reported that while tacrolimus,
a macrolide immunosuppressant that chiefly interferes with T cell
activation, was found to decrease RANKL expression in an arthri-
tis mice model compared to control mice, tacrolimus significantly
induced SOCS3 mRNA expression in the arthritis model (47).
Another well-studied inducer of SOCS3 gene expression is
TGF-β (13, 15). It was shown that TGF-β induces a rapid and con-
tinuous increase in SOCS3 mRNA expression in non-committed
precursors and mature osteoclasts (13). Moreover, the combined
treatment of TGF-β and RANKL led to a sustained increase in
SOCS3 mRNA levels that were about seven times control lev-
els (13). SOCS3 expression is also induced by IL-3, IL-4, IL-13,
GM-CSF, IFN-β, and IFN-γ in a number of cells, including bone
marrow cells via STAT-dependent transcription (13, 16).
Contradictory roles of SOCS3 in osteoclasts have been
reported. One study showed that during periods of TGF-β treat-
ment and low bone resorption, TGF-β stimulates osteoclast differ-
entiation to support survival through transcriptional activation
of SOCS3; however, when bone resorption levels are high, TGF-β
inhibit both differentiation and mature osteoclast apoptosis (15).
A second study reported that overexpression of SOCS3 mRNA in
osteoclasts promotes osteoclastogenesis via suppression of IFN-β
(13). In contrast, a third study found that non-arthritic SOCS3–
/∆vav mice, which lack SOCS3 protein in the hematopoietic and
endothelial cell compartment, exhibited increased basal osteoclast
expression in vivo compared with wild type (WT) mice, suggesting
a negative regulatory role for SOCS3 (17). Despite these discrep-
ancies, it has been clearly established that SOCS3 plays a key role
in regulation of both inflammation and bone.
SOCS3 IN CHONDROCYTES
Increased chondrocyte apoptosis is one possible pathologic mech-
anism responsible for cartilage damage. Several studies have shown
that the expression and function of SOCS3 in chondrocytes
play critical roles in preventing cartilage loss in conditions such
as osteoarthritis (OA) and rheumatoid arthritis (RA) (18–22).
Specifically, SOCS3 works by inhibiting the signaling pathways
of pro-inflammatory cytokines such as IL-6 via STAT3 phos-
phorylation suppression, which in turn would no longer inhibit
chondrocyte proliferation.
To assess the role of SOCS3 in chondrocytes, rat chondrosar-
coma chondrocytes (RCS) were used to model fibroblast growth
factor receptor (FGR) three-related skeletal dysplasia (18, 20).
When activated, FGRs attenuate cartilage growth. STAT activation
is a key feature of the initiation and perpetuation of arthritis in
mice (23). Stimulation of RCS cells with FGF 2 which binds FGR3
led to STAT3 phosphorylation, but not STAT1, STAT5, or STAT6
phosphorylation (20). Moreover, protein levels of STAT3 increased
as well; however, comparison with mRNA levels indicated that
FGF2 might additionally accumulate STAT3 independent of tran-
scription (20). It was shown that FGF2 also increased levels of
STAT3 protein in mouse limb explant cultures (20). When RCS
chondrocytes were treated with IFN-γ, IL-6, IL-11, and leukemia
inhibitory factor (LIF), STAT3 was activated. Interestingly, how-
ever, the combined treatment of the cytokines and FGF2 impaired
STAT activation (20). In addition to IL-1, FGF2 has also been
shown to induce SOCS3 in both RCS chondrocytes (20) and in
primary cultured articular chondrocytes (18). Since FGF2 inhibits
cytokine (IL-6 and IFN-γ)-mediated activation of STAT3 in RCS
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cells and also up-regulates SOCS3 protein levels, it is possible that
the inhibition of STAT3 is due to the increased presence of SOCS3,
which regulates STAT3 in a negative feedback loop. However,
whether the expression of functionally active SOCS3 negatively
regulates IL-6 signaling in chondrocytes has yet to be investigated.
When SV40 large T antigen-immortalized H4 chondrocytes
derived from hip articular cartilage of C57BL/6 mice were treated
for 2 h with IL-1, a cytokine whose levels are elevated in arthritic
synovial fluid (19), phosphorylation of STAT3 was induced.
Importantly, RT-PCR revealed that IL-1 stimulation increased lev-
els of SOCS3 mRNA in chondrocytes by about 700% compared
with control levels, and Western blot analysis showed a promi-
nent increase in SOCS3 protein as well (19). Direct stimulation of
chondrocytes with IL-1-induced high SOCS3 protein levels both
in vivo and in vitro (19). Furthermore, forced expression of SOCS3
in H4 chondrocytes via transduction inhibited phosphorylation of
STAT3, indicating antagonistic activity of SOCS3 (19).
Recently, studies have also shown the increased expression of
SOCS3 in human arthritic chondrocytes compared with control
chondrocytes (22, 24). For example, there was greater expression
of SOCS3 mRNA in chondrocytes obtained from the cartilage of
patients with OA and RA than in chondrocytes from the carti-
lage of patients with femoral neck fracture (22). Furthermore, a
significant positive correlation between increased SOCS3 expres-
sion and MMP-13 expression was observed (22). These findings
demonstrate the important function of SOCS3 protein in human
cartilage pathology. Whether SOCS3 plays a protective role in
cartilage through anti-inflammatory pathways or functions as a
mediator for destructive mediators such as MMP-13 remains to
be determined.
SOCS3 IN SYNOVIOCYTES
An important role for SOCS3 is the suppression of signal trans-
duction pathways that lead to excessive inflammation and bone
loss. Inhibition of STAT and JAK is considered a critical thera-
peutic aim in order to prevent bone destruction in RA (25–27).
On the other hand, SOCS3 is closely related to osteoclastoge-
nesis, thus making it a prime candidate of interest to study in
bone diseases. Synovial fibroblasts (SFs) are cells that play critical
roles in the pathogenesis of chronic inflammatory diseases; par-
ticularly, SFs participate in cartilage destruction and producing
pro-survival cytokines, chemokines, and angiogenic factors (28).
Many of these cytokines, such as IL-6, activate STAT3, which in
turn suppresses pro-apoptotic pathways. One study demonstrated
that STAT3 is important for RA synoviocyte survival (28). Inter-
estingly, Han et al. shows that the inhibition of p38 MAP kinase
suppresses the production of IL-1β-induced cytokines and MMPs
in a human fibroblast-like synoviocyte cell line, MH7A, while it
induces the expression of SOCS3 and interferon regulatory factor
1 (IRF-1) (29). In another recent study, Mori et al. shows that IL-1β
and TNF-α-initiated IL-6-STAT3 activation plays a critical role in
mediating the expression of inflammatory cytokines and receptor
of nuclear factor kappa B ligand (RANKL) in murine osteoblas-
tic and fibroblastic cells (27). Importantly, they demonstrate that
the drug CP690, 550, or Tofacitnib, a Jak3 inhibitor, significantly
inhibits collagen-induced arthritis (CIA) through reducing the
expression of IL-6 family cytokines and RANKL, suppressing both
inflammation and joint destruction (27). These results together
with their previous reports that overexpression of SOCS3 or dom-
inant negative STAT3 in joints effectively ameliorated CIA models
(30) indicate that IL-6–STAT3–mediated cytokine amplification
loop plays a key role in promoting sustained inflammation and
joint destruction during arthritis, and this loop can be negatively
regulated by SOCS3.
Tacrolimus was shown to exhibit anti-arthritic actions by reg-
ulating inflammatory cytokine production in RA (31, 32). Addi-
tionally, tacrolimus prevents differentiation of cells into mature
osteoclasts, thereby conferring protection against bone resorp-
tion (33, 34). One recent study reported that tacrolimus signif-
icantly increased SOCS3 mRNA levels in affected joints in an
arthritis mouse model induced by K/BxN serum when compared
to non-treated arthritic mice (35). Furthermore, treatment with
tacrolimus in addition to IL-6/sIL-6R stimulation significantly
decreased receptor activator of NF-κB ligand (RANKL) expression
as well as JAK2 and STAT3 phosphorylation in fibroblast-like syn-
oviocytes (35). Western blot analysis revealed that tacrolimus also
increased SOCS3 protein expression in a dose-dependent manner
(35). Interestingly, while down-regulation of JAK-STAT activation
induced the expression of SOCS3, the expression of SOCS1, and
CIS1 did not change (35). Since fibroblast-like synoviocytes con-
stitute a potent source of RANKL production in patients with
RA, the blockade of RANKL expression by the SOCS3 pathway
in fibroblast-like synoviocytes may be important in the regula-
tion of osteoclast differentiation for bone erosion in RA. Together,
these data suggest that the JAK2-STAT3-SOCS3 signaling path-
way in fibroblast-like synoviocytes may play a critical role in the
pathogenesis of RA.
SOCS3 IN PERIODONTAL DISEASES
Porphyromonas gingivalis (P. gingivalis) is a gram-negative bac-
terium involved in the pathogenesis of periodontal disease. P.
gingivalis regulates pathways that control cytokine signaling; for
example, P. gingivalis infection of epithelial cells can stimulate the
production of pro-inflammatory cytokines such as IL-1β and sup-
press anti-inflammatory cytokines such as IL-10 (36). P. gingivalis
also modulates cell apoptosis via JAK signal transduction as well
as STAT and Akt pathways (36).
The human genome consists of many miRNAs, which are
known to be key players in pathway network control of cellular
processes such as inflammation and apoptosis (36). One recent
study showed that P. gingivalis significantly induces the expres-
sion of 14 miRNAs in primary cultures of gingival epithelial cells
(36). Among them, miR-203 has defined targets, and has been
implicated to regulate cytokine signaling. Thus, targeting miR-203
in periodontitis may have important implications in therapy, as
miR-203 expression has been reported in RA and psoriatic arthri-
tis (36). One known cytokine downstream of miR-203 is SOCS3
(36). It was shown that P. gingivalis infection reduced levels of
SOCS3 mRNA as it induced miR-203 and that regulation of SOCS3
by P. gingivalis was dependent on miR-203 in gingival epithelial
cells (36). Furthermore, the decrease of SOCS3 increased acti-
vation of STAT3 (36). Interestingly, in an unpublished study, we
determined that LPS from the P. gingivalis pathogen significantly
increases levels of SOCS3 in THP-1 cells, a human monocytic cell
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FIGURE 1 |The complex role of SOCS3 in bone cells. SOCS3 is
expressed in osteoblasts, osteoclasts, chondrocytes, and synoviocytes. In
osteoblasts, SOCS3 inhibits E. coli LPS-induced IL-6 and MMP-13
expression by suppressing CCAAT/enhancer-binding protein β activity. In
contrast, SOCS3 positively regulate osteoclastogenesis by blocking the
inhibitory effect of inflammatory cytokines on receptor activator of the
NF-kappaB ligand-mediated osteoclast differentiation signals. SOCS3
deficiency in the hematopoietic and endothelial cell compartment results
in osteoclast generation and bone destruction. In chondrocytes, SOCS3
inhibits the Stat3-mediated inflammatory pathway. In contrast, there is an
increased expression of SOCS3 in human arthritic chondrocytes compared
with control chondrocytes. There is a strong positive correlation between
SOCS3 expression and MMP-13 suppression. Tacrolimus, an
immunosuppressant, was shown to exhibit anti-arthritic effects by
regulating inflammatory cytokine production in RA. Additionally, tacrolimus
prevents differentiation of cells into mature osteoclasts, thereby conferring
protection against bone resorption. In fibroblast-like synoviocytes,
tacrolimus increases SOCS3 protein expression while it decreases
receptor activator of NF-κB ligand (RANKL) expression as well as JAK2 and
STAT3 phosphorylation.
line. However, we also showed that P. gingivalis LPS stimulation of
primary calvarial osteoblasts did not change SOCS3 mRNA levels
compared to control cells.
To determine the relationship between inflammatory cytokines
potentially induced by P. gingivalis and SOCS3, human PDL cells
were stimulated with pro-inflammatory cytokines such as IL-
1β and IL-6 (37). RT-PCR and Western blot analysis revealed
that IL-1β and IL-6 both induced SOCS3 expression in PDL
cells. Moreover, overexpression of SOCS3 suppressed secretion
of IL-8 and monocyte chemoattractant protein (MCP)-1 in
PDL cells by inhibiting phosphorylation in downstream signal-
ing (37). Taken together, these results suggest that the induction
of pro-inflammatory cytokines by P. gingivalis can lead to SOCS3
regulation of destructive cytokine signaling, thus potentially pre-
venting excessive inflammation and bone loss seen in chronic
periodontal diseases. Furthermore, these data suggest that a failure
of SOCS3 expression of function plays a role in osteolytic peri-
odontal lesions. However, this hypothesis needs to be determined
by in vivo animal models.
SOCS3 AND INFLAMMATORY ARTHRITIS
A key characteristic feature of any form of arthritis is bone
loss. Bone and cartilage destruction result from overwhelming
osteoclast activity compared with osteoblast activity and from
prolonged inflammation. These conditions can arise from exces-
sive production of pro-inflammatory cytokines. For example, in
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OA, articular chondrocytes induce the production of IL-1β and
TNF-α (21).
It was reported that STAT3 levels correlated positively with
inflammation severity (38). Interestingly, immunohistochemistry
comparison of STAT3 activation in RA and OA patients with
anti-phospho-STAT3-specific antibodies showed that STAT3 was
activated in the nucleus of RA synovial cells but not in that of
OA cells (30). Furthermore, Northern blot analysis revealed that
cytokine signal suppressor (CIS3) was strongly expressed in RA
synovial tissues from RA patients, but only scarcely in OA synovial
tissues (30). Since SOCS3 inhibits STAT3 signaling in a number of
cells, it is not surprising that SOCS3 was also shown to negatively
regulate innate and adaptive immunity in both antigen-induced
arthritis (AIA) and CIA (30).
Recent studies demonstrate that T helper 17 (Th17) cells play
a critical role in the development of arthritis (39, 40). Interest-
ingly, Mori et al. suggest that STAT3 pathway contributes to RA
by inducing Th17 cell development (27). Importantly, SOCS3 is
a major regulator of IL-23-mediated STAT3 phosphorylation and
Th17 generation (41). Furthermore, TGF-β promotes Th17 cell
development via inhibition of SOCS3 (42). These studies suggest
that SOCS3 may regulate the development of arthritis through
Th17 differentiation.
To determine the function of endogenous SOCS3 in arthritis,
one study compared the severity of mBSA/IL-1-induced inflam-
matory arthritis in WT, Socs3+/∆vav, and Socs−/∆vav mice (17).
Socs3+/∆vav mice were used as controls. Socs−/∆vav mice under-
went deletion of SOCS3 in all hematopoietic and endothelial cells
(17). The Socs−/∆vav mice exhibited characteristics of exacerbated
inflammatory arthritis, such as dramatic synovial hyperplasia,
intense pannus erosion into the bone with increased inflamma-
tory exudate, reduced basal trabecular bone volume, and lack
of synovial granulomas (17). Furthermore, cartilage destruction
and proteoglycan loss was significantly increased in SOCS3 defi-
cient mice. Socs−/∆vav mice also displayed elevated numbers of
osteoclasts, which correlates with the bone loss seen in arthritis
(17). This observation suggests that endogenous SOCS3 inhibits
basal osteoclastogenesis and that in non-arthritic Socs−/∆vav mice,
osteoblasts express SOCS3 to compensate for bone loss resulting
from increased osteoclast activity. Macrophages are important for
arthritis (43). Specifically, SOCS3 inhibits M1 macrophage polar-
ization and inflammation (44). These findings together suggest
that SOCS3 is an indispensable negative regulator of inflammation
in arthritis (17, 30).
CONCLUSION
In the past decade, the expression and function of SOCS3 have
been intensively studied in immune cells such as macrophages
and T cells. Most of these studies are focused on the regulation
loop of cytokine-STAT/JAK-SOCS3. In addition, SOCS3 expres-
sion in these cells can also be induced by a variety of other
inflammatory stimuli including bacterial products (45). How-
ever, detailed mechanisms by which SOCS3 regulates signaling
pathways distinct from STAT/JAK remain incomplete and con-
troversial. Interestingly, recent studies indicate that SOCS3 is also
expressed in many other cell types including osteoblasts, osteo-
clasts, chondrocytes, and synoviocytes (Figure 1). However, the
expression of SOCS3 in these cells in response to various inflam-
matory stimuli and its function in bone inflammatory diseases are
still largely unknown. In addition, SOCS3 seems to have oppos-
ing functions in regulating inflammatory responses in these cells
(Figure 1). For example, while SOCS3 inhibits LPS-induced IL-
6 and MMP-13 expression in osteoblasts (4, 5), SOCS3 as well
as SOCS1 positively regulate osteoclastogenesis by blocking the
inhibitory actions of inflammatory cytokines on receptor activa-
tor of the NF-kappaB ligand-mediated osteoclast differentiation
signals (46). Thus, the role of SOCS3 during bone inflamma-
tion is complex; more details of the SOCS3 pathway are necessary
for a better understanding of the mechanisms of various bone
inflammatory diseases.
In addition, the net effect of SOCS3 may be dependent on
when and in which cell type SOCS3 plays a major role. In this
regard, use of inducible SOCS3 knock-out mice in different bone
cells may be a realistic future direction. Although the functional
investigation of SOCS3 in the bone inflammatory response is still
a challenge, these endeavors will be fruitful. Elucidating SOCS3
function in various bone cells will identify prospective targets for
a new generation of drugs that target inflammation-associated
bone diseases. Moreover, identification of SOCS3 interacting
proteins will lead to a better understanding how SOCS3 regu-
lates bone inflammatory responses through transcriptional and/or
post-transcriptional control of downstream genes such as IL-6 and
MMP-13.
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